FDA halts imports of several Sun Pharma drugs made in India due to outstanding quality issues
A drug manufacturing site that has garnered a lot of attention from the FDA this year has been handed an import alert from the US regulator, blocking certain drugs from entering the country.
According to the FDA, Sun Pharma’s plant in the city of Halol, India has been given an import alert, as of yesterday, which means that the regulator has enough evidence to detain products without examination and refuse their entry into the US market until the issues are corrected and the facility is compliant with cGMP.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.